Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Remicade can improve psoriasis symptoms

An international team led by a dermatologist at The University of Manchester has found that treatment with the emerging drug infliximab, marketed as Remicade, can quickly and significantly improve psoriasis symptoms.

From The University of Manchester 13 Oct 2005

Potential oral drug for rheumatoid arthritis

A potential oral drug for rheumatoid arthritis (RA) may encourage women to treat their condition earlier rather than later because it is less arduous than currently available treatments. Early treatment is important because RA most often develops between the ages of 35 and 50 and is two- to three times more prevalent in women.

26 Sep 2005

Adalimumab and methotrexate is about five times more effective than methotrexate alone for rheumatoid arthritis

For people with long-standing rheumatoid arthritis, combined treatment with the new "biologic" drug adalimumab and methotrexate is about five times more effective than methotrexate alone, according to a new systematic review of studies.

15 Aug 2005

Biologic treatments to treat the physical symptoms of psoriasis

More than 4.5 million adults in the United States have been diagnosed with psoriasis and 21 percent of those have moderate to severe psoriasis. This chronic condition, characterized by thick, red, scaly plaques that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

21 Jul 2005

Arthritis patients still suffer as drugs guidelines are ignored

Access to drugs whose use was approved by the UK's National Institute for Health and Clinical Excellence (NICE) three years ago is still being denied to patients with severe rheumatoid arthritis.

7 Jun 2005

Remicade shows promise in treating ulcerative colitis

Results from two Phase III, placebo-controlled clinical trials found that approximately two-thirds of patients with moderate to severe, active ulcerative colitis (UC) treated with Remicade (infliximab, 5mg/kg) demonstrated a significant improvement in symptoms.

16 May 2005

Experts call for improved access to treatment for psoriatic arthritis

MPs gathered at the House of Commons on Tuesday (April 5th) as experts and patient groups urged members of parliament to lobby for improved access to treatment for patients with psoriatic arthritis, a little known and poorly understood condition in which patients experience symptoms of both psoriasis and arthritis.

6 Apr 2005

Tumour Necrosis Factor alpha (TNF-alpha) blocking agents cause skin disease

Members of the second most important family of drugs used to treat rheumatoid arthritis can cause serious dermatological conditions in a quarter of patients under treatment, reveals a study published in the journal Arthritis Research and Therapy.

3 Apr 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

Promising new evidence for the optimal use of biologic therapies for rheumatoid arthritis

A major cause of pain and disability, rheumatoid arthritis (RA) is also potentially the most treatable form of chronic arthritis. Researchers, doctors, and patients agree that a group of drugs called disease-modifying antirheumatic drugs (DMARDs) can effectively reduce joint pain and stiffness.

7 Jan 2005

Remicade (infliximab) is able to reverse the symptoms of rheumatoid arthritis

A new study published today in Arthritis & Rheumatism demonstrates that Remicade (infliximab) is able to reverse the symptoms of the debilitating disease rheumatoid arthritis (RA) in patients who are newly diagnosed.

5 Nov 2004

Analysis shows Remicade reduces pain associated with Crohn's disease

According to a new sub-analysis from the ACCENT I (A Crohn's disease Clinical trial Evaluating infliximab in a New long-term Treatment regimen) trial patients who received a three-dose induction regimen of Remicade experienced a significantly greater reduction in pain as assessed by four different pain questions after ten weeks, compared with patients who received a single dose of Remicade.

2 Nov 2004

Study underscores the relative safety of infliximab, when used properly

Rheumatoid arthritis patients receiving the recommended starting dose (3mg/kg) of infliximab (REMICADE®) have no more serious rate of infections than do patients taking methotrexate alone

18 Oct 2004

Pneumococcal vaccinations help protect patients with rheumatoid arthritis against serious pneumococcal infections of the lungs, brain, blood, and ears

Rheumatoid arthritis patients have an approximately two-fold increased morbidity and mortality in infections compared to a population without the disease.

18 Oct 2004

Study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

The study will examine how much of an improvement in pain, stiffness, function and other symptoms is needed before patients consider the change important.

7 Aug 2004

New clinical study to determine how people with rheumatoid arthritis evaluate improvements in disease symptoms

A new clinical study to determine how people with rheumatoid arthritis (RA) evaluate improvements in disease symptoms will be carried out by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the Department of Health and Human Services' National Institutes of Health.

5 Aug 2004

European recommended approval of Remicade for treatment of psoriatic arthritis

Committee for Medicinal Products for Human Use of the European Agency for the Evaluation of Medicinal Products has issued a positive opinion recommending approval of expanded labeling for REMICADE(R) (infliximab), in combination with methotrexate, for treatment of active and progressive psoriatic arthritis (PsA) in patients who have responded inadequately to disease modifying anti- rheumatic drugs (DMARDs).

2 Aug 2004

Remicade shows improvement in both the arthritis and psoriasis associated with psoriatic arthritis

In this trial, REMICADE provided a 70 percent improvement (as measured by ACR 70) in symptoms of arthritis in nearly one-third of patients, compared with only 2 percent of patients on placebo at 24 weeks.

10 Jun 2004

Study comparing the efficacy of REMICADE® to Azathioprine alone and in combination With REMICADE®

Centocor, Inc., and Schering-Plough Corporation announced today the initiation of the SONIC (Study of Immunomodulator Naive patients in Crohn's Disease) trial that will evaluate the efficacy of REMICADE® (infliximab) versus azathioprine, a conventional immunosuppressive agent, alone and versus the combination of both drugs for the treatment of patients with Crohn's disease.

18 May 2004

FDA approves new drug Enbrel for psoriasis

The U.S. Food and Drug Administration has approved the biologic drug etanercept (brand name Enbrel) to treat chronic, moderate to severe plaque psoriasis in adults.

1 May 2004